Experience with autologous bone marrow transplantation (ABMT) in patients with impaired left ventricular ejection fraction (LVEF) or heart failure (HF) is limited. We identified 308 consecutive patients who underwent ABMT for Hodgkin's or non-Hodgkin's lymphoma at our institution (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003). Patient characteristics, clinical course and overall survival were compared between patients with preserved (X50%) or impaired (o50%) LVEF. Of the 308 patients identified, 20 had baseline impaired LVEF (four with LVEF p40%, all NYHA class I-II HF). None of the patients with post-ABMT echocardiogram had worsened LVEF (n ¼ 7). Among the 20 patients with impaired LVEF, four patients had reversible cardiac complications post-ABMT (including worsening HF). The two deaths observed in the impaired LVEF group were both due to noncardiac causes. The 5-year survival was similar between patients with preserved and impaired LVEF (P ¼ 0.43). Careful selection of patients with stable, mild-to-moderate HF and impaired LVEF for ABMT can achieve similar long-term survival. As medical care for HF and ABMT improves, the exclusion criteria for ABMT with regard to HF and impaired LVEF should be re-examined.
Hodgkin's lymphoma; Hodgkin's disease; left ventricular ejection fraction Assessment of pre-transplant organ function has been a routine part of the eligibility criteria for bone marrow transplant protocols for over 30 years. Most eligibility criteria require preserved cardiac function, which is arbitrarily defined as left ventricular ejection fraction (LVEF) of X50% in order to proceed with autologous hematopoietic stem cell transplantation (ABMT). These eligibility criteria began prior to the routine use of primed peripheral blood progenitor cells (PBPCs) that accelerate engraftment and reduce toxicity associated with ABMT.
The rationale for denying eligibility for patients with impaired cardiac function is that such patients will have significantly increased treatment-related mortality that will offset the potential clinical benefit of the transplant. However, the data documenting the usefulness of such eligibility criteria cardiac function are sparse. Serious cardiac complications have been associated with induction chemotherapy and radiation administered during the conditioning phase of ABMT, particularly in regimens involving cyclophosphamide and total body irradiation. 1 Clinically, these patients can present early with signs and symptoms of progressive heart failure (HF) and carditis. Myocardial biopsies from patients who undergo these conditioning regimens have revealed hemorrhagic perimyocarditis, endothelial damage, capillary microthrombi and acute fibrinous pericarditis. 2, 3 Fortunately, cardiotoxicity from conditioning therapy is uncommon occurring in o1% of patients in a recent series. 4 Given the documented life-saving potential of ABMT for many subsets of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease, arbitrary transplant exclusion criteria seem dated.
Some suggest that pre-treatment LVEF (even in ranges considered unimpaired) are predictive of post transplant cardiac complications. 5 Others suggest that cardiac function may not even be affected post-bone marrow transplantation (BMT) after 1-7 months of follow-up. 6 The reported incidence of cardiotoxicity has also varied among different investigators, probably reflecting bias in patient selection differences in the preparative regimen and a lack of a universal grading system for cardiac toxicity. 7, 8 Very little evidence exists on the long-term outcomes of patients with impaired LVEF who undergo BMT. The purpose of this retrospective analysis is to investigate the clinical course and survival of patients who undergo BMT with preserved LVEF (X50%) or impaired LVEF (o50%).
Methods

Study population
This is a retrospective review of 308 patients with NHL or Hodgkin's disease undergoing ABMT at our institution from February 1996 to January 2003 comparing clinical outcome in consecutive patients with an LVEF of X50% vs those with an LVEF of o50%. Ethics committee approval was obtained according to the requirements set by the Cleveland Clinic Foundation institutional review board. The inclusion criteria for our study were registry patients who had an autologous BMT for either Hodgkin's or NHL.
PBPC mobilization and transplant protocol
PBPCs were mobilized with G-CSF alone (n ¼ 113, 36.7%). or etoposide plus G-CSF (n ¼ 195, 63.3%). A minimum of 2.0 Â 10 6 CD34 þ cells/kg was required to proceed with ABMT. All patients received a chemotherapy-only highdose preparative regimen of busulfan, cyclophosphamide and etoposide (busulfan 14 mg/kg, etoposide 60 mg/kg and cyclophosphamide 120 mg/kg).
Supportive care: Patients were hospitalized for the delivery of high-dose chemotherapy and discharged after adequate hematologic recovery occurred. Platelet or RBC transfusions were routinely administered when the platelet count was o15 Â 10 9 /l or the hemoglobin was o8.5 g/dl, respectively. All blood products were irradiated prior to infusion. Broad-spectrum antibiotics were administered for febrile neutropenic episodes. G-CSF was routinely given on day þ 5 after transplant.
Measurement of cardiac function
All patients underwent pre-transplant cardiac evaluation by two-dimensional transthoracic echocardiography. LVEF is estimated visually as well as measured using biplane Simpson's rule.
Study design
The available medical records of each enrolled patient were reviewed to follow the clinical course of these patients for at least 100 days post-BMT. The 100-day mortality and 100-day nonrelapse mortality were compared between patients with preserved and impaired left ventricular function. All patients with an LVEF of o50% had their entire hospital chart reviewed by an independent physician investigator (ST).
Statistical analysis
Categorical variables are summarized as frequencies and percentages, and compared between LVEF groups using the w 2 test. Continuous variables are summarized as the median and range, and compared between groups using the Wilcoxon's rank-sum test. Survival is defined as months from ABMT to death or the most recent follow-up. Survival was estimated using the Kaplan-Meier method, and compared between groups using the log-rank test. Cox's proportional-hazard analysis was used to determine the relationship between LVEF and survival, adjusting for variables that differed between LVEF groups at Po0.10 and adjusting for variables that were prognostic for survival at Po0.10. Six such variables were identified: age, number of prior chemotherapy regimens, prior radiation therapy, months from diagnosis to ABMT, disease status and lactic dehydrogenase. A multivariable Cox's model was generated which included these six variables and LVEF, regardless of statistical significance in the model. All analyses were conducted using SAS s software (SAS, Cary, NC, USA). All statistical tests were two-sided; Po0.05 was used to indicate statistical significance.
Results
Of these 308 eligible patients, 288 patients had preserved cardiac function (preserved LVEF group) and 20 patients had pre-ABMT LVEF o50% (impaired LVEF group). Among the 20 patients with pre-ABMT LVEF o50%, two had a history of myocardial infarction (10%). Patients were followed for a mean of 19 months in the impaired LVEF group and 21.8 months in the preserved LVEF group. The median number of CD34 þ cells infused was 7.2 Â 10 6 cells/ kg. Baseline characteristics are summarized in Table 1 . The median time from diagnosis of the patients' primary disease to BMT was 31.6 months (range 4.6-167.2 months) in those with impaired LVEF and 14.5 months in the preserved LVEF group (range 3.2-207.6 months). Mean hospital stay for the two groups were similar (2272 days in the impaired LVEF group and 2375 days in the preserved LVEF group). The mean neutrophil engraftment time (defined by an absolute neutrophil count 4500 cells/m 3 ) and platelet engraftment time (defined by a count of 20 000/mm 3 ) were similar in both groups (1071 and 1575 days, respectively).
Long-term clinical outcomes and underlying causes of death at follow-up in our cohort were shown in Table 2 . Overall, the 5-year survival was similar between patients with impaired and preserved LVEF (Figure 1 ). None of the four patients with an LVEF o40% died within 100 days. There were no deaths or significant complications with fluid management in the entire patient population related to cardiac toxicity. When the survival comparison is adjusted for six variables that either differ between groups or which are prognostic for survival, this difference remains nonsignificant (P ¼ 0.42; Table 3 ).
In the impaired LVEF group, all patients were found to have stable New York Heart Association (NYHA) functional class I-II HF prior to ABMT as documented by a consulting cardiologist based on a detailed review of their charts. All 20 patients were treated with either angiotensinconverting enzyme-inhibitors or angiotensin receptor blockers, and 12 patients (60%) were treated with betaadrenergic blockers prior to ABMT. Only four patients in this group had documented cardiac complications immediately following ABMT: one patient had mildly progressive signs and symptom of HF and three patients had episodes of atrial fibrillation and/or nonsustained ventricular tachycardia. Seven of the 20 patients underwent post-ABMT echocardiographic evaluation and none had significant worsening of cardiac performance. Also of note, no patients had a documented change in NYHA class over the complete follow-up period.
Discussion
Our retrospective data of ABMT for NHL or Hodgkin's disease performed since 1996 confirms that patients with an LVEF o50% can safely receive ABMT provided their HF symptoms are well controlled (NYHA functional class I-II). Based on this preliminary analysis of a single-center's experience, there is evidence to suggest that in carefully selected group of patients with pre-existing impaired cardiac functions may tolerate contemporary ABMT regimens without significant cardiovascular sequelae. As a result, we have removed LVEF criteria as absolute exclusions for patients undergoing ABMT at the Cleveland Clinic Foundation. We do require that patients with an LVEF o50% have a cardiac assessment performed by a cardiologist. However, the ultimate decision to perform a Clinical outcomes of patients with impaired LVEF WHW Tang et al transplant has to be an overall assessment of risks and benefits.
When the clinical practice of BMT began several decades ago, it was reasonable to include transplant protocol eligibility criteria assessing the underlying organ function, including cardiac, renal and pulmonary function. The toxicity associated with the transplant itself, especially considering that initially most transplants were allogeneic, was substantial. The toxicities of high-dose preparative regimens, and graft-versus-host disease, were just beginning to be defined, and opportunistic infections were problematic. The requirement of robust cardiac and other organ function was entirely appropriate at that time. Fortunately, the past 30 years has seen significant clinical progress in supportive care of both allogeneic and autologous transplantation. In particular, the routine use of primed PBPCs over the past decade has dramatically reduced toxicities of autologous transplantation. Currently, mortality rates for ABMT are only 1-2%. Despite this progress, most transplant protocols still have rigid eligibility criteria that potentially deny patients the life-saving benefit of ABMT. Furthermore, nonmyeloablative allogeneic transplantation offers the potential life-saving benefits of transplantation to older and less robust patients. Given the dramatic improvements that have been made in our understanding of graft-versus-host disease, opportunistic infection and supportive care in general, a recent review 7 has suggested that the entire field of BMT re-examine the issue of prognostic factors both pre-and post transplant. Table 4 is a summary of the sparse literature examining pre-transplant cardiac assessment and clinical outcome. Much of these data focus on allogeneic bone marrow transplant recipients. Of those examining autologous transplantation, the bulk of the data suggest that a pre-transplant LVEF does not predict short-term mortality or cardiac toxicity.
The greatest concern with regard to ABMT in impaired LVEF has been the use of high-dose chemotherapeutic regimen with known cardiotoxic effects. Although there were four patients with LVEF o40% prior to ABMT who did suffer cardiac complications in the immediate post transplantation period, none had experienced fatal outcomes. The two deaths that occurred in this impaired LVEF group were attributable to noncardiac causes that included relapse of lymphoma and pneumonia. Furthermore, there is also a growing recognition that LVEF itself There are notable weaknesses in our study. The outcomes of data on ABMT in both the impaired and preserved LVEF group were retrospective and observational in nature. Thus, selection and referral biases may influence our findings. Another weakness is that only four patients had LVEF o40% and this may have contributed to lower number of adverse outcomes overall. All patients had relatively stable NYHA class I-II function, a cohort that would be expected to do better overall.
Conclusions
Although impaired LVEF has been regarded as a contraindication to ABMT, patients with stable, mild-to-moderate HF and impaired LVEF appear to tolerate ABMT without significant short-term cardiovascular complications and have a similar long-term survival similar to those with preserved LVEF. As medical care for HF and ABMT improves, the exclusion criteria for ABMT regarding HF and impaired LVEF should be re-examined on a case-bycase basis. Factors determining the ineligibility of ABMT in patients with impaired cardiac function should be further examined.
